Moderna (MRNA) downside has played out, HSBC raises rating
Tweet Send to a Friend
Moderna (NASDAQ: MRNA) was raised to Hold from Reduce at HSBC on Friday, with the firm raising the price target ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


